ACSS2-Mediated Metabolic-Epigenetic Crosstalk Drives Fulvestrant Resistance and Represents a Novel Therapeutic Target
Ayca Nazli Mogol, Jin Young Yoo, Alicia Arredondo Eve…·Zeynep Madak‐Erdogan
This study identifies ACSS2-mediated metabolic-epigenetic crosstalk as a driver of Fulvestrant resistance in ER+ breast cancer and presents ACSI as a potential therapeutic target.